The Measles “Booster Problem” Is Mostly the Wrong Problem

The Measles “Booster Problem” Is Mostly the Wrong Problem

Why waning antibody titers, selected nonresponders and a forgotten 1960s vaccine cohort should not be conflated into a coming crisis of measles susceptibility in the elderly

Geert Vanden Bossche

Aug 30, 2026

Take-home message

Robert Malone’s recent essay, “The Measles Booster Problem” correctly identifies several real observations: vaccine-induced measles antibody (Ab) titers can decline; some individuals respond poorly to measles vaccination; additional MMR doses do not invariably produce large or durable Ab increments; and Americans who received the failed formalin-inactivated measles vaccine in 1963–1967 represent a legitimate catch-up problem [11].

Malone News

The Measles Booster Problem

Two decay curves…

Read more

19 days ago · 344 likes · 109 comments · Dr. Robert W. Malone

A sequel to my previous critique

A serum Ab concentration is an individual measurement; measles risk is an ecological outcome! The same person with the same Ab titer faces a very different risk in a population where transmission is effectively interrupted than in a dense cluster of susceptible people during an outbreak [1].

His Substack article, “The Measles Booster Problem,” compounds this problem. It moves from waning titers to poor booster responses, from poor booster responses to a proposed failure of live-attenuated vaccine replication, from there to the need for a fundamentally different vaccine platform, and then to a specific historical cohort that may have received an inactivated vaccine. These are not successive steps in a single causal chain. They are distinct immunological and epidemiological questions. Putting them under one alarming umbrella creates complexity without creating clarity.

1. Waning Ab is not the same as waning protection

The starting observation is uncontroversial: after two doses of measles-containing vaccine, average circulating Ab concentrations decline with time. But Malone repeatedly lets this serological observation do more inferential work than it can support. The best available review literature explicitly notes that individuals with low or even undetectable neutralizing Ab (NAb) can retain immunological memory and may remain protected from clinical measles [2]. The 2024 England modelling study likewise found evidence compatible with very slow secondary waning ─ about 0.039% per year in the preferred model ─ while concluding that vaccine protection remains high for decades and that most transmission remains connected to unvaccinated people [3].

This is precisely why a declining Ab titer cannot be treated as an approaching ‘immunological cliff’ in older vaccinees. NAb is an important correlate of protection but it is not an on/off switch for clinical susceptibility. Protection depends on pre-existing NAbs, immune memory, overall immune competence, the intensity of exposure, and ─critically for measles─ the probability that exposure occurs at all! Malone acknowledges parts of this biology, yet his rhetoric repeatedly returns the reader to the more dramatic image of a vaccinated cohort whose protection is fading away.

However, high titers of pre-existing NAbs are useful as a stand-alone correlate of protection because, depending on their concentration and neutralizing capacity, they may even prevent productive infection and thus approach sterilizing immunity.

But the converse does not follow: high circulating NAb titers are not required for protection against measles disease and, in populations with established protective herd immunity against measles, may not even be required to prevent infection.

Previously primed B- and T helper-cell memory can contribute to rapid control after exposure while population-level immunity further reduces the probability and intensity of exposure itself. Accordingly, a low or waning serum NAb titer cannot by itself be equated with loss of meaningful protection.

2. Fiebelkorn did not demonstrate a failed booster in a susceptible
population

The Fiebelkorn MMR3 study is particularly poorly suited to support a generalized ‘booster failure’ narrative. Of 662 young adults before a third dose, only one (0.2%) was seronegative and 23 (3.5%) had low NAb concentrations. One year after MMR3, no participant was seronegative and only 10 of 617 had low titers. Only 3.2% showed a fourfold Ab rise but that is hardly surprising in a cohort that was already overwhelmingly immune before vaccination [4]. A small fold-rise in an already high-titer population is not evidence that clinically meaningful protection has failed to return; in an already strongly immune cohort there is limited quantitative headroom for a dramatic fold-rise. More importantly, modest MMR3 responsiveness does not establish that residual Ab prevented vaccine-virus replication. Type-I interferon (IFN) can itself restrict measles-virus replication in human PBMCs, and vaccine/laboratory-adapted strains can induce stronger type-I IFN responses than wild-type strains [12,13]. Interindividual variation in this innate antiviral response could therefore constrain replication and antigen amplification of the attenuated virus independently of, or alongside, pre-existing Ab.
Because Fiebelkorn measured neither vaccine-virus replication nor IFN responses, the study cannot establish the proposed causal sequence of ‘residual Ab ð insufficient replication ð failed durable boosting’.

Most importantly, Fiebelkorn did not measure the endpoint Malone’s interpretation ultimately implies: subsequent susceptibility to wild-type measles disease. The study did not show that people whose increase in NAb titer was modest went on to develop measles at an elevated rate. Its conclusion was appropriately narrow: the data did not support routine administration of a third MMR dose.

That is quite different from showing that the existing live-attenuated platform is incapable of restoring useful protection.

3. Anichini studied a selected nonresponder phenotype ─ not ordinary
aging vaccinees

The Anichini study is even more easily overgeneralized. It enrolled only 24 people who were seronegative years after completing a two-dose schedule. Eleven seroconverted after one additional dose; thirteen required another. In a subset of nonresponders, measles stimulation failed to elicit measurable changes in T-, B- or NK-cell populations, whereas rubella stimulation did, suggesting a measles-specific defect rather than generalized immune failure [5]. This is an unusual, biologically selected population.

Such subjects should not be used as a proxy for millions of ordinary twice-vaccinated adults whose circulating titers have merely declined with age.

Persistent non-responsiveness, primary vaccine failure, secondary Ab waning after a good initial response and a modest incremental response in an already immune person are different phenotypes. Collapsing them into a single ‘booster problem’ is exactly the kind of conceptual simplification that makes a complicated article sound mechanistically unified when it is not.

4. The proposed mechanism is possible but far from established as the
mechanism

Malone’s mechanistic explanation is that residual Ab neutralizes the attenuated vaccine virus so rapidly that it cannot replicate sufficiently to drive renewed germinal-center activity and seed a durable population of long-lived plasma cells.
Pre-existing Ab can certainly interfere with measles vaccination and maternal Ab interference is well documented. But even that literature warns against reducing the phenomenon to simple neutralization of vaccine virus: maternal Ab also suppresses responses to non-replicating antigens and can inhibit B-cell activation through mechanisms such as FcγRIIB-dependent feedback and epitope masking [6].

More importantly, the adult booster studies cited by Malone did not directly demonstrate his proposed causal sequence: ‘residual NAb ð insufficient vaccine-virus replication ð inadequate germinal-center re-entry ð failure to generate long-lived plasma cells’.
No measurement of in-vivo vaccine-virus replication in these adults establishes that chain. A plausible mechanism should not be mistaken for the mechanism.

5. Host-genetic heterogeneity provides an obvious alternative
explanation

The measles vaccinomics literature makes a single-mechanism explanation particularly implausible. Vaccine responsiveness varies substantially among otherwise healthy individuals and has a demonstrable host-genetic component. A genome-wide study of 2,872 vaccinees identified significant associations between measles NAb responses and variants in CD46, the receptor efficiently used by vaccine strains, and IFI44L, an IFN-stimulated gene. Functional analyses linked a CD46 variant to altered exon usage and receptor isoform expression [7]. Reviews and candidate-gene studies have additionally implicated HLA, cytokine and cytokine-receptor genes, innate sensing pathways and other antiviral-response genes [2,7].

That biology offers multiple independent bottlenecks.

Receptor expression or isoform usage can alter entry of the attenuated virus. Innate and IFN responses can restrict its replication. HLA polymorphism can alter presentation of measles peptides to helper T cells. Cytokine variation can alter the inflammatory and T follicular helper cell environment. B-cell repertoire, germinal-center dynamics and plasma-cell survival can determine the magnitude and durability of the final humoral response.

Two people receiving the same live vaccine therefore need not experience the same effective antigenic exposure or generate the same immune landscape.

This point becomes especially difficult for Malone’s model in a repeatedly seronegative person.

If residual circulating Ab were the dominant obstacle to vaccine-virus replication, the person with the least Ab should provide the vaccine virus with the greatest opportunity to replicate. Yet some such individuals remain poor responders after additional doses.
That observation is much more naturally accommodated by intrinsic host-response heterogeneity than by an explanation centered on residual Ab.

6. A new non-replicating measles vaccine does not logically follow

Malone then makes another leap: because an attenuated virus allegedly cannot replicate adequately in the presence of residual Ab, he argues for a vaccine that behaves immunologically like a live vaccine but does not require viral replication. This is a research hypothesis, not the logical solution compelled by the data. If host HLA, receptor biology, innate restriction, T-cell help or B-cell differentiation contributes to poor responsiveness, changing the antigen-delivery platform does not automatically solve the problem. And if an individual is already strongly immune, limited incremental boosting may simply reflect biological limitations rather than a defective vaccine design.

Malone’s proposed solution is even less convincing than his diagnosis. His claim that “the scientific case for a better measles vaccine is straightforward” rests on the assumption that the current live-attenuated vaccine is intrinsically deficient because it cannot generate sufficiently durable plasma-cell immunity in the presence of pre-existing Ab. That conclusion does not follow from the evidence.

A live-attenuated vaccine is, immunologically, an exceptionally powerful vaccine platform precisely because it replicates, amplifies antigen in vivo, activates innate antiviral pathways and presents antigen through the same cellular machinery engaged during natural infection.

Its attenuation reduces pathogenicity and intrinsic infectiousness, but it does not convert it into an immunologically weak platform. On the contrary, among conventional vaccine technologies, live-attenuated vaccines are generally the closest approximation to natural infection in the breadth and durability of the immune response they induce.

It is therefore highly speculative to assume that a non-replicating measles platform, whether based on adjuvanted protein, viral vectors, virus-like particles or nucleic acid technology, would outperform the existing live-attenuated measles vaccine in generating durable neutralizing immunity or long-lived plasma-cell responses. Such platforms may have theoretical advantages in selected circumstances, but there is presently no evidence that they can reproduce, let alone surpass, the combined antigen amplification, innate stimulation and adaptive priming achieved by a successful live-attenuated measles vaccine.

The problem is therefore not that the current vaccine platform is demonstrably too weak, but that Malone interprets the absence of large or durable Ab increments after repeated dosing as evidence of platform failure.

That inference confuses the biology of an already immune host with the intrinsic immunogenicity of the vaccine. In a previously primed individual, limited additional Ab expansion may reflect immune feedback, rapid restriction of vaccine-virus replication, host-genetic determinants, interferon-mediated antiviral control or simply limited immunological room for further quantitative amplification.
None of these observations demonstrates that a fundamentally different vaccine platform would generate more useful or more durable protection against measles in immunologically naïve or previously primed individuals.

The scientific case for replacing the live-attenuated measles vaccine is therefore not “straightforward.”

On the contrary, any proposed alternative would have to demonstrate that it can match or exceed what the current live-attenuated measles vaccine already achieves in terms of clinical protection, durability, breadth of immunity and suppression of transmission. At present, there is no convincing evidence that a non-replicating measles vaccine would do so.

7. The real exception: the 1963–1967 killed-vaccine cohort

There is, however, one part of Malone’s article with which I substantially agree. In the United States, fewer than one million people received a formalin-inactivated measles vaccine between 1963 and 1967. That product was ineffective and was associated with atypical measles after subsequent exposure. Current CDC guidance therefore recommends that people who received the killed vaccine ─ or a measles vaccine of unknown type before 1968 ─ be revaccinated with a live attenuated measles-containing vaccine if they have no contraindication [8,9].

This is a genuine catch-up problem. But it is not evidence for an age-related “booster problem.”

It is a problem of uncertain or defective primary immunization. Immunologically, these people belong with other individuals who may not have acquired reliable measles immunity in the first place. They should therefore be identified and managed as a specific immunity gap, just as we identify unvaccinated children or other genuinely susceptible individuals.

Malone himself belongs to the relevant age band, which may explain his understandable interest in the issue. But the historical cohort must not be used rhetorically to amplify concern among all older vaccinees. Birth between 1957 and 1966 does not mean that a person received the killed vaccine; fewer than one million people did. The CDC recommendation turns on documented or uncertain vaccination history in the 1963–1967 period, not on age alone [8].

There is also a practical product issue worth discussing separately. In the United States, as in the European Union, monovalent measles vaccine is no longer commercially available; measles vaccination is supplied through combination vaccines such as MMR or MMRV [9,10]. This is unfortunate because it removes the option of selectively immunizing against measles when vaccination against mumps and rubella is neither required nor desired

8. The public-health priority is the immunologically naïve population
─ not Ab chasing in the elderly

This is where I most strongly object to Malone’s framing. His subtitle ─ “Vaccine immunity fades, and another dose does not restore it” ─ and his repeated references to people now entering their sixties and seventies create the impression of a looming susceptibility crisis among previously vaccinated older adults. He tells readers in that age range that they now have a question to ask at their next physician visit and describes the cohort as moving up the severity curve. Whatever his intention, this is an alarm-oriented framing.

The dominant epidemiological problem is elsewhere.

Measles resurgence in elimination settings is driven primarily by insufficient and uneven vaccination coverage, importation, and clusters of immunologically naïve or under-immunized people.

Even the England model that detects slow waning concludes that the vaccine remains highly protective for decades and that most transmission is connected to unvaccinated individuals [3]. Current U.S. guidance likewise emphasizes maintaining the routine two-dose schedule and closing genuine vaccination gaps [8,9].

The rational priority is therefore not to chase Ab titers in elderly vaccinees and infer susceptibility from them. It is to maintain high and sufficiently homogeneous immunity among the immunologically naïve people continually entering the population ─ primarily children, but also susceptible migrants and adults with missing or inadequate vaccination histories ─and to identify true high-risk gaps such as recipients of the 1960s killed vaccine.

9. Herd immunity is not a footnote; it is the integrating principle

Whatever the individual mechanism of vaccine responsiveness ─ whether determined by receptor biology, innate signaling, HLA presentation, cytokines, B-cell biology or prior Abs ─ effective population-level protection (i.e., ‘herd protection’) benefits everyone by reducing the chance that infectious virus reaches them. This indirect protection is especially valuable to nonresponders, infants too young to be fully vaccinated and people who cannot receive a live vaccine because of severe immunosuppression ─ regardless of their genetic background or Ab titers!.

This does not mean that population immunity makes individual immunity irrelevant. Nor does it mean that every person receives an identical degree of indirect protection. Measles is so transmissible that local pockets of susceptibility matter enormously.

But that is exactly the point: the clinically relevant risk is generated jointly by individual immune status, exposure intensity and the immune status of the surrounding population [1,3].

Hence the paradox in Malone’s argument. He worries about the immunocompromised and proposes exposure avoidance, immune globulin and vaccination of close contacts ─ measures whose effectiveness ultimately depends on the same principle he underweights elsewhere: reducing the probability that virus reaches a susceptible person. At population scale, that principle is herd protection.

Conclusion: too many problems forced into one story!

Malone’s article contains several correct observations but the synthesis is not convincing. Waning Ab does not equal loss of clinical protection. A weak fold-rise after MMR3 in an already immune cohort is not proof of vaccine-platform failure. A tiny cohort of persistent seronegative nonresponders cannot be generalized to ordinary aging vaccinees. Pre-existing Ab may limit a live vaccine response but it has not been shown to be the universal mechanism of poor boosting as host-genetic heterogeneity offers multiple alternative explanations. A speculative mechanism does not establish the need for a non-replicating replacement vaccine.

Most importantly, the article risks directing fear toward the wrong population. Older vaccinated adults should not be led to believe that declining Ab titers place them on the edge of an inevitable measles-susceptibility cliff. The urgent task is much more prosaic and much more important:

Preserve high population immunity, prevent clusters of susceptible people, vaccinate the immunologically naïve, identify genuine primary-immunity gaps and maintain excellent outbreak surveillance.

The 1963–1967 killed-vaccine problem deserves attention precisely because it is a real primary-immunization problem. It should not be used to support a broader narrative that the aging vaccinated population now requires a new booster strategy.

In short: one plausible mechanism should not be mistaken for the mechanism, one unusual subgroup should not be mistaken for a generation, and waning serology should not be mistaken for waning population protection.

References

1. Vanden Bossche G. Protective Measles Immunity Cannot Be Reduced to a Cutoff in an Immunological Readout. Voice for Science and Solidarity. Aug 29, 2026.

2. Haralambieva IH, Kennedy RB, Ovsyannikova IG, Schaid DJ, Poland GA. Current perspectives in assessing humoral immunity after measles vaccination. Expert Rev Vaccines. 2019;18(1):75–87. doi:10.1080/14760584.2019.1559063.

3. Robert A, Suffel AM, Kucharski AJ. Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study. Lancet Public Health. 2024;9:e766–e775. doi:10.1016/S2468-2667(24)00181-6.

4. Fiebelkorn AP, et al. Measles virus neutralizing antibody response, cell-mediated immunity, and IgG antibody avidity before and after a third dose of measles-mumps-rubella vaccine in young adults. J Infect Dis. 2016;213(7):1115–1123. doi:10.1093/infdis/jiv555.

5. Anichini G, et al. Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity. J Med Virol. 2024;96(12):e70135. doi:10.1002/jmv.70135.

6. Niewiesk S. Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune Responses, and Possible Vaccination Strategies. Front Immunol. 2014;5:446. doi:10.3389/fimmu.2014.00446.

7. Haralambieva IH, et al. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. Hum Genet. 2017;136(4):421–435. doi:10.1007/s00439-017-1768-9.

8. Centers for Disease Control and Prevention. Measles Vaccination. Updated Apr 29, 2026. Guidance for recipients of inactivated or unknown-type measles vaccine before 1968.

9. Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases, Chapter 7: Measles. Monovalent measles vaccine is not available in the United States.

10. European Medicines Agency (EMA). Measles: authorised vaccines against measles. In April 2025, the centrally authorised measles-containing vaccines available in the EU were M-M-RVaxPro and ProQuad. Accessed Aug 2026.

11. Malone RW. The Measles Booster Problem. Malone News. Aug 20, 2026.

12. Leopardi R, Hyypiä T, Vainionpää R. Effect of interferon-alpha on measles virus replication in human peripheral blood mononuclear cells. APMIS. 1992;100(2):125–131. doi:10.1111/j.1699-0463.1992.tb00850.x.

13. Shingai M, Ebihara T, Begum NA, et al. Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J Immunol. 2007;179(9):6123–6133. doi:10.4049/jimmunol.179.9.6123.

‍